Inobrodib (Synonyms: CCS1477)

Name: Inobrodib
Brand: MedChemExpress
SKU: HY-111784
Rating: 5.0 (11 reviews)

Cat. No.: HY-111784 Purity: 99.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.

For research use only. We do not sell to patients.

CAS No. : 2222941-37-7

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Inobrodib:

EP300/CBP-IN-2 Get quote

11 Publications Citing Use of MCE Inobrodib

Cell Proliferation/Viability Assay

RT-PCR

: Inobrodib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jun 3;16(1):432. [Abstract]; Western blot and qRT-PCR analyses were performed to evaluate the PD-L1 levels in RCC10 and RCC4 cells treated with DMF/FHIN1, both in the absence and presence of 20 μM A485 or 100 nM CCS1477, an inhibitor of p300.

: Inobrodib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Oct;26(19):4766-4793. [Abstract]; RT-qPCR for eRNA of NKX2-2, CCND1 and PPP1R1A enhancers following 6 h treatment of A-485, CCS1477 (1 μM), and dCBP-1 treatment in SKNMC cells.

: Inobrodib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Oct;26(19):4766-4793. [Abstract]; Cell viability of SKNMC and A673 cells treated with A-485, CCS1477 (1 μM) and Dual combination for 6 days measured by CellTiter-Glo.

: Inobrodib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 5;15(1):4770. [Abstract]; IC50 values of the CBP/p300 inhibitors CP-C27, A-485, and Inobrodib (6 days), the EZH2 inhibitor tazemetostat, and the EZH1/EZH2 inhibitor valemetostat in HEK293T, JMU-RTK-2 +SMARCB1, and JMU-RTK-2 -SMARCB1 cells.

: Inobrodib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jan 25;52(2):625-642. [Abstract]; Bar graphs depict KLK3 gene expression analysis in VCaP ENZ 0, VCaP ENZ 3w, 22Rv1 ENZ 0, and 22Rv1 ENZ 3w cells treated with or without Dex in the presence or absence of 0.1 or 1 μM of indicated inhibitor (A-485, CCS1477, I-BET762, BRM014).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

p300/CBP^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CWR22R	IC₅₀	0.42 μM Compound: 4; CCS1477	Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition by Celltiter-Glo assay Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition by Celltiter-Glo assay	[PMID: 34962793]
CWR22R	IC₅₀	184 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human 22Rv1 cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human 22Rv1 cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]
CWR22R	IC₅₀	184 nM Compound: 5; CCS1477	Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human 22Rv1 cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
EOL1	IC₅₀	< 3 μM Compound: 4; CCS1477	Antiproliferative activity against human EOL1 cells Antiproliferative activity against human EOL1 cells	[PMID: 38649304]
Hep 3B2	IC₅₀	1.928 μM Compound: 4; CCS1477	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
HepG2	IC₅₀	0.869 μM Compound: 4; CCS1477	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
KG-1	IC₅₀	17.04 μM Compound: 4; CCS1477	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
KG-1	IC₅₀	< 3 μM Compound: 4; CCS1477	Antiproliferative activity against human KG-1 cells Antiproliferative activity against human KG-1 cells	[PMID: 38649304]
L02	IC₅₀	20 μM Compound: 4; CCS1477	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
LNCaP	IC₅₀	0.06 μM Compound: 4; CCS1477	Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition by Celltiter-Glo assay Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition by Celltiter-Glo assay	[PMID: 34962793]
LNCaP	IC₅₀	412 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human LNCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human LNCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]
LNCaP	IC₅₀	412 nM Compound: 5; CCS1477	Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human LNCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
LNCaP C4-2B	IC₅₀	1.65 μM Compound: 4; CCS1477	Antiproliferative activity against human LNCaP C4-2B cells assessed as inhibition of cell growth by Celltiter-Glo assay Antiproliferative activity against human LNCaP C4-2B cells assessed as inhibition of cell growth by Celltiter-Glo assay	[PMID: 34962793]
MOLM-13	IC₅₀	102.5 nM Compound: 4; CCS1477	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell-Titer Glo assay	[PMID: 38649304]
MOLM-16	IC₅₀	0.37 μM Compound: 4; CCS1477	Antiproliferative activity against human MOLM16 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis Antiproliferative activity against human MOLM16 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
MOLM-16	IC₅₀	12.9 nM Compound: 4; CCS1477	Antiproliferative activity against human MOLM16 cells incubated for 72 hrs by Cell-Titer Glo assay Antiproliferative activity against human MOLM16 cells incubated for 72 hrs by Cell-Titer Glo assay	[PMID: 38649304]
MOLT-4	IC₅₀	0.247 μM Compound: 4; CCS1477	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
MV4-11	IC₅₀	0.014 μM Compound: 4; CCS1477	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 120 hrs by celltiter glo luminescence analysis Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 120 hrs by celltiter glo luminescence analysis	[PMID: 38829718]
MV4-11	IC₅₀	20.4 nM Compound: 4; CCS1477	Antiproliferative activity against human MV4-11 cells incubated for 120 hrs by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells incubated for 120 hrs by Cell-Titer Glo assay	[PMID: 38649304]
OPM-2	IC₅₀	30 nM Compound: 4; CCS1477	Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK8 assay Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK8 assay	[PMID: 39356741]
RPMI-8226	IC₅₀	0.082 μM Compound: 4; CCS1477	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 6 days by CCK-8 assay	[PMID: 39356741]
SK-HEP1	IC₅₀	4.679 μM Compound: 1; CCS1477	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 5 days by CCK-8 assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 5 days by CCK-8 assay	[PMID: 38316017]
THP-1	IC₅₀	< 3 μM Compound: 4; CCS1477	Antiproliferative activity against human THP-1 cells Antiproliferative activity against human THP-1 cells	[PMID: 38649304]
VCaP	IC₅₀	195 nM Compound: 5; CCS1477	Antiproliferative activity against human VCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay Antiproliferative activity against human VCaP cells assessed as cell growth inhibition incubated for 4 days by celtiter-glo luminescent assay	[PMID: 38477974]
VCaP	IC₅₀	53.6 nM Compound: 3; CCS1477	Antiproliferative activity against AR positive human VCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay Antiproliferative activity against AR positive human VCaP cells assessed inhibition of cell growth measured after 4 days by CellTiter-Glo Luminescent cell viability assay	[PMID: 38530938]

In Vitro

Inobrodib binding to cellular histones in an in-cell BRET assay gives an IC₅₀ of 19 nM for p300 and 1060 nM for BRD4. Inobrodib shows potent growth-inhibitory activity in VCaP, 22Rv1, and LNCaP95 (all IC₅₀ < 100 nM) that express both AR-FL and AR-V7^[1].
? Inobrodib (0-3000 nM; 48 hours) reduces expression of AR-regulated genes (KLK2, KLK3, and TMPRSS2) in both 22Rv1 and LNCaP95 cells. Inobrodib also reduces C-MYC protein expression in both 22Rv1 and LNCaP95 cells and AR-V7 protein expression in 22Rv1 cells, without clear impact on AR-FL protein expression in 22Rv1 and LNCaP95 cells. Inobrodib reduces C-MYC mRNA and downstream AR and C-MYC signaling in 22Rv1 and C4-2 cells at 16 hours. Inobrodib regulates AR signaling by affecting the recruitment of CBP, p300, and AR-FL to known AR binding sites, and has the potential to abrogate persistent AR signaling in CRPC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Inobrodib (10-30 mg/kg; oral gavage; 10 or 20 mg/kg daily (QD) or 30 mg/kg every other day (QOD) for 28 days) suppresses growth of a 22Rv1 mouse xenograft model with associated reduction in AR signaling^[1].
? Inobrodib (20 mg/kg; oral gavage; daily for 8 days) decreases AR and AR-V7 signaling and inhibits growth in a patient- derived model of lethal prostate cancer (NOD/SCID gamma (NSG) male castrated mice)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Noncastrated male athymic nude mice^[1]
Dosage:	10-30 mg/kg
Administration:	Oral gavage; at 10 or 20 mg/kg daily (QD) or at 30 mg/kg every other day (QOD) for 28 days
Result:	Affected tumor growth at 10 mg/kg daily, 20 mg/kg daily, and 30 mg/kg every other day.

Clinical Trial

Molecular Weight

534.60

Formula

C₃₀H₃₂F₂N₄O₃

CAS No.

2222941-37-7

Appearance

Solid

Color

White to off-white

SMILES

O=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (187.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8706 mL	9.3528 mL	18.7056 mL
5 mM	0.3741 mL	1.8706 mL	3.7411 mL
10 mM	0.1871 mL	0.9353 mL	1.8706 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.68 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.68 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (259 KB) HNMR (402 KB) RP-HPLC (227 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Rasool RU, et al. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov. 2021;11(5):1011-1013. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8706 mL	9.3528 mL	18.7056 mL	46.7639 mL
	5 mM	0.3741 mL	1.8706 mL	3.7411 mL	9.3528 mL
	10 mM	0.1871 mL	0.9353 mL	1.8706 mL	4.6764 mL
	15 mM	0.1247 mL	0.6235 mL	1.2470 mL	3.1176 mL
	20 mM	0.0935 mL	0.4676 mL	0.9353 mL	2.3382 mL
	25 mM	0.0748 mL	0.3741 mL	0.7482 mL	1.8706 mL
	30 mM	0.0624 mL	0.3118 mL	0.6235 mL	1.5588 mL
	40 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1691 mL
	50 mM	0.0374 mL	0.1871 mL	0.3741 mL	0.9353 mL
	60 mM	0.0312 mL	0.1559 mL	0.3118 mL	0.7794 mL
	80 mM	0.0234 mL	0.1169 mL	0.2338 mL	0.5845 mL
	100 mM	0.0187 mL	0.0935 mL	0.1871 mL	0.4676 mL

Inobrodib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Inobrodib2222941-37-7CCS1477CCS 1477CCS-1477Epigenetic Reader DomainoralbromodomainproliferationprostatecancernudemicehistonesInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Inobrodib (Synonyms: CCS1477)

Customer Review

Other Forms of Inobrodib:

Inobrodib Related Antibodies

11 Publications Citing Use of MCE Inobrodib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Inobrodib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Inobrodib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report